1.0The Medical Xchangehttps://themedicalxchange.com/en/Raising the Rate of Successful GERD Control: Focus on Improved Pharmacokinetics of Acid Suppressant Therapy - The Medical Xchangerich600338<blockquote class="wp-embedded-content" data-secret="pm3duC7lfT"><a href="https://themedicalxchange.com/en/2011/05/07/digestive-disease-week-ddw-2011/">Raising the Rate of Successful GERD Control: Focus on Improved Pharmacokinetics of Acid Suppressant Therapy</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://themedicalxchange.com/en/2011/05/07/digestive-disease-week-ddw-2011/embed/#?secret=pm3duC7lfT" width="600" height="338" title="“Raising the Rate of Successful GERD Control: Focus on Improved Pharmacokinetics of Acid Suppressant Therapy” — The Medical Xchange" data-secret="pm3duC7lfT" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://themedicalxchange.com/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
https://themedicalxchange.com/wp-content/uploads/2011/05/DDW_slides_EN_Fig_1.jpg22001650Chicago - Proton pump inhibitors (PPIs) are the standard for control of gastroesophageal reflux disease (GERD), but there is increasing appreciation for their limitations. Although PPIs were the first pharmacological agent with a high rate of success for healing esophagitis, a substantial minority of patients report incomplete control of symptoms on standard doses. This has generated a variety of strategies to improve symptom relief, most often a twice-daily regimen to replace the standard once-daily morning dose. The rationale for an extra dose of PPI is based on the physiology of acid pump production. Although PPIs irreversibly bind to acid pumps to prevent acid production, new pumps form constantly, particularly with meal stimulation. While the added dose of a PPI can bind to and inhibit the pumps that form subsequent to the first dose, it invites the potential for reduced compliance, defeating this potential advantage. A new approach is based on improving PPI pharmacokinetics.